Estimating 'costs' for cost-effectiveness analysis

PharmacoEconomics

Volumn 26, Issue 9, 2008, Pages 745-751

  Miners, Alec ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER PREVENTION; CLINICAL EFFECTIVENESS; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; GUIDE TO THE METHODS OF TECHNOLOGY APPRAISAL; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESPAN; MARGINAL COSTING; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RESOURCE MANAGEMENT; REVIEW; TECHNOLOGY APPRAISAL PROGRAM; UNITED KINGDOM;

COSTS AND COST ANALYSIS; GREAT BRITAIN; HEALTH POLICY; HUMANS; MODELS, ECONOMETRIC; POLICY MAKING; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 51149108309     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826090-00005     Document Type: Review

References (22)

1. National Institute for Health and Clinical Excellence. Guide to the technology appraisals process. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf [Accessed 2007 Jun 4]
2. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13 (5): 437-52
3. Dakin HA, Devlin NJ, Odeyemi IAO. 'Yes', 'No' or 'Yes, but'? Multinomial modelling of NICE decision-making. Health Pol 2006; 77 (3): 352-67
4. Morris SN, Devlin N, Parkin D. Economic analysis in health care. Chichester: John Wiley and Sons, Ltd, 2007
5. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
6. Claxton K, Sculpher M, Culyer AJ. Mark versus Luke? Appropriate methods for the evaluation of public health interventions [research paper]. York: University of York, Centre for Health Economics, 2007 Nov [online]. Available from URL: http://www.york.ac.uk/inst/che/pdf/rp31.pdf [Accessed 2008 Jul 11]
7. Brouwer WB, van Exel NJ, Baltussen RM, et al. A dollar is a dollar is a dollar: or is it? Value Health 2006; 9 (5): 341-7
8. Johnston K, Buxton MJ, Jones DR, et al. Assessing the costs of health care technologies in clinical trials. Health Technol Assess 1999; 3 (6): 1-76
9. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York: Oxford University Press, 1996
10. Mushlin AI, Fintor L. Is screening for breast cancer cost-effective? Cancer 1992; 69 Suppl. 7: 1957-62
11. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997; 17: 382-9
12. Moskowitz M. Costs of screening for breast cancer. Radiol Clin North Am 1987; 25: 1031-7
13. National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ CG58FullGuideline.pdf [Accessed 2008 May 1]
14. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3 (4): 233-345
15. Briggs A, Gray A. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999; 319 (7210): 635-8
16. Briggs A, Clark T, Wolstenholme J, et al. Missing, presumed at random: cost analysis of incomplete data. Health Econ 2003; 12 (5): 377-92
17. Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001
18. Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ 2004; 23 (3): 443-70
19. Young T. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005; 23 (12): 1229-42
20. Calvert NW, Morgan AB, Catto JW, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003; 88 (1): 31-5
21. UK Department of Health. NHS reference costs 2006-07. London: DH, 2008 Feb [online]. Available from URL: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/Pub licationsPolicyAndGuidance/DH_082571 [Accessed 2008 Mar 1]
22. Buxton MJ, Acheson R, Caine R, et al. Costs and benefits of the heart transplant programmes at Harefield and Papworth Hospitals [research report no.2]. London: Department of Health and Social Security, 1985